Isoniazid

Generic Name
Isoniazid
Brand Names
Isonarif, Isotamine, Isotamine B, Rifamate, Rifater
Drug Type
Small Molecule
Chemical Formula
C6H7N3O
CAS Number
54-85-3
Unique Ingredient Identifier
V83O1VOZ8L
Background

Antibacterial agent used primarily as a tuberculostatic. It remains the treatment of choice for tuberculosis.

Indication

Isoniazid is used for the treatment of all forms of tuberculosis in which organisms are susceptible. It is also used in combination with rifampin and pyrazinamide.

Associated Conditions
Active Tuberculosis, Mycobacterium kansasii infection, Late phase Tuberculosis
Associated Therapies
-

The Treatment of Tuberculosis in HIV-Infected Patients

Phase 3
Completed
Conditions
First Posted Date
2001-08-31
Last Posted Date
2021-11-04
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Target Recruit Count
650
Registration Number
NCT00001033
Locations
🇺🇸

Johns Hopkins Adult AIDS CRS, Baltimore, Maryland, United States

🇺🇸

Univ. of Miami AIDS CRS, Miami, Florida, United States

🇺🇸

Cook County Hosp. CORE Ctr., Chicago, Illinois, United States

and more 9 locations

Prophylaxis Against Tuberculosis (TB) in Patients With Human Immunodeficiency Virus (HIV) Infection and Suspected Latent Tuberculous Infection

Not Applicable
Completed
Conditions
First Posted Date
2001-08-31
Last Posted Date
2021-11-04
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Target Recruit Count
600
Registration Number
NCT00000959
Locations
🇺🇸

Comprehensive AIDS Alliance of Detroit, Detroit, Michigan, United States

🇺🇸

Clinical Directors Network of Region II, New York, New York, United States

🇺🇸

Denver CPCRA / Denver Public Hlth, Denver, Colorado, United States

and more 11 locations

Preventive Treatment Against Tuberculosis (TB) in Patients With Human Immunodeficiency Virus (HIV) Infection and Confirmed Latent Tuberculous Infection

Not Applicable
Completed
Conditions
First Posted Date
2001-08-31
Last Posted Date
2021-11-02
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Target Recruit Count
2000
Registration Number
NCT00000638
Locations
🇺🇸

Moses H Cone Memorial Hosp, Greensboro, North Carolina, United States

🇺🇸

State of MD Div of Corrections / Johns Hopkins Univ Hosp, Baltimore, Maryland, United States

🇺🇸

Johns Hopkins Hosp, Baltimore, Maryland, United States

and more 73 locations

Prophylaxis Against Tuberculosis (TB) in Patients With Human Immunodeficiency Virus (HIV) Infection and Confirmed Latent Tuberculous Infection

Not Applicable
Completed
Conditions
First Posted Date
2001-08-31
Last Posted Date
2021-11-02
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Target Recruit Count
2000
Registration Number
NCT00000636
Locations
🇺🇸

AIDS Research Consortium of Atlanta, Atlanta, Georgia, United States

🇺🇸

Philadelphia FIGHT, Philadelphia, Pennsylvania, United States

🇺🇸

Boston Dept of Health and Hosps, Boston, Massachusetts, United States

and more 22 locations

A Prospective Study of Multidrug Resistance and a Pilot Study of the Safety of and Clinical and Microbiologic Response to Levofloxacin in Combination With Other Antimycobacterial Drugs for Treatment of Multidrug-Resistant Pulmonary Tuberculosis (MDRTB) in HIV-Infected Patients.

Not Applicable
Completed
Conditions
First Posted Date
2001-08-31
Last Posted Date
2021-11-03
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Target Recruit Count
525
Registration Number
NCT00000796
Locations
🇺🇸

Montefiore Drug Treatment Ctr / Bronx Municipal Hosp, Bronx, New York, United States

🇺🇸

Cook County Hosp, Chicago, Illinois, United States

🇺🇸

Bronx Lebanon Hosp Ctr, Bronx, New York, United States

and more 18 locations

Metabolism of Antituberculosis Drugs in HIV-Infected Persons With Tuberculosis

Not Applicable
Completed
Conditions
First Posted Date
2001-08-31
Last Posted Date
2011-03-02
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Target Recruit Count
50
Registration Number
NCT00000950
Locations
🇺🇸

Emory Univ, Atlanta, Georgia, United States

🇺🇸

Beth Israel Med Ctr, New York, New York, United States

🇺🇸

Queens Med Ctr, Honolulu, Hawaii, United States

and more 10 locations

Effectiveness of Anti-HIV Therapy (HAART) in HIV-Infected Patients With Tuberculosis

Phase 1
Completed
Conditions
First Posted Date
2001-08-31
Last Posted Date
2008-09-11
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Target Recruit Count
44
Registration Number
NCT00004736
Locations
🇺🇸

Univ of California / San Diego Treatment Ctr, San Diego, California, United States

🇺🇸

Univ of Southern California / LA County USC Med Ctr, Los Angeles, California, United States

🇺🇸

Vanderbilt Univ Med Ctr, Nashville, Tennessee, United States

and more 7 locations

A Pilot Study of Methodology to Rapidly Evaluate Drugs for Bactericidal Activity, Tolerance, and Pharmacokinetics in the Treatment of Pulmonary Tuberculosis Using Isoniazid and Levofloxacin

Phase 1
Completed
Conditions
First Posted Date
2001-08-31
Last Posted Date
2008-08-08
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Target Recruit Count
44
Registration Number
NCT00000778
Locations
🇺🇸

Tulane Univ Med School, New Orleans, Louisiana, United States

🇺🇸

UCLA Med Ctr, Los Angeles, California, United States

🇺🇸

Harbor - UCLA Med Ctr, Torrance, California, United States

and more 7 locations

Intensive Pharmacokinetics of the Nelfinavir-Rifabutin Interaction in Patients With HIV-Related Tuberculosis Treated With a Rifabutin-Based Regimen

Not Applicable
Conditions
First Posted Date
2001-07-04
Last Posted Date
2005-06-24
Lead Sponsor
National Center for Research Resources (NCRR)
Registration Number
NCT00018083
Locations
🇺🇸

Duke University Medical Center, Durham, North Carolina, United States

Randomized Study of Interventions to Enhance Adherence to Isoniazid Prevention Therapy for Tuberculosis in Injection Drug Users

Not Applicable
Conditions
First Posted Date
2000-02-25
Last Posted Date
2005-06-24
Lead Sponsor
National Institute on Drug Abuse (NIDA)
Target Recruit Count
300
Registration Number
NCT00004740
© Copyright 2024. All Rights Reserved by MedPath